Context is key for FLT3-ITD

被引：0
|
作者：
Meyer, Sara E. [1 ]
机构：
[1] Thomas Jefferson Univ, Philadelphia, PA 19144 USA
来源：
BLOOD | 2023年 / 141卷 / 12期
关键词：
INTERNAL TANDEM DUPLICATION; KNOCK-IN; MYELOPROLIFERATIVE DISEASE; MUTATIONS; LEUKEMIA;
D O I：
10.1182/blood.2022019135
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this issue of Blood, Li et al1 report age and co-mutation contexts wherein FLT3 internal tandem duplication (ITD) orchestrates unique transcriptional and epigenetic programs to deliver distinct functional outputs from myeloid progenitor cells.
引用
收藏
页码：1373 / 1374
页数：2
相关论文
共 50 条
  • [21] Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML
    H Wu
    C Hu
    A Wang
    E L Weisberg
    W Wang
    C Chen
    Z Zhao
    K Yu
    J Liu
    J Wu
    A Nonami
    L Wang
    B Wang
    R M Stone
    S Liu
    J D Griffin
    J Liu
    Q Liu
    Leukemia, 2016, 30 : 754 - 757
  • [22] Novel Small Molecule FLT3 Inhibitors for the Treatment of FLT3-ITD AML
    Melgar, Katelyn
    Walker, MacKenzie
    Jiang, Jian-kang
    Wilson, Kelli
    Mulloy, James C.
    Thomas, Craig J.
    Starczynowski, Daniel T.
    BLOOD, 2015, 126 (23)
  • [23] Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML
    Wu, H.
    Hu, C.
    Wang, A.
    Weisberg, E. L.
    Wang, W.
    Chen, C.
    Zhao, Z.
    Yu, K.
    Liu, J.
    Wu, J.
    Nonami, A.
    Wang, L.
    Wang, B.
    Stone, R. M.
    Liu, S.
    Griffin, J. D.
    Liu, J.
    Liu, Q.
    LEUKEMIA, 2016, 30 (03) : 754 - 757
  • [24] The GSK3β/Mcl-1 axis is regulated by both FLT3-ITD and Axl and determines the apoptosis induction abilities of FLT3-ITD inhibitors
    Qiu, Yang
    Li, Ying
    Chai, Meng
    Hua, Huiming
    Wang, Rui
    Waxman, Samuel
    Jing, Yongkui
    CELL DEATH DISCOVERY, 2023, 9 (01)
  • [25] Physiologic hypoxia of 6% O2 regulates FLT3-ITD expression and function in AML cell-lines harbouring a FLT3-ITD mutation
    Sironi, S.
    Wagner, M.
    Drolle, H.
    Vasold, J.
    Hiddemann, W.
    Fiegl, M.
    ONKOLOGIE, 2012, 35 : 117 - 118
  • [26] Subclinical Minute FLT3-ITD Clone Can be Detected in Clinically FLT3-ITD-Negative Acute Myeloid Leukemia
    Yokoyama, Shota
    Onozawa, Masahiro
    Yoshida, Shota
    Miyashita, Naoki
    Kimura, Hiroyuki
    Takahashi, Shogo
    Matsukawa, Toshihiro
    Fujisawa, Shinichi
    Miki, Kosuke
    Hidaka, Daisuke
    Hashiguchi, Junichi
    Wakasa, Kentaro
    Ibata, Makoto
    Takeda, Yukari
    Shigematsu, Akio
    Fujimoto, Katsuya
    Tsutsumi, Yutaka
    Mori, Akio
    Ishihara, Toshimichi
    Kakinoki, Yasutaka
    Kondo, Takeshi
    Teshima, Takanori
    BLOOD, 2022, 140 : 9094 - 9095
  • [27] FLT3-ITD Allele Frequency Is an Independent Prognostic Factor for Poor Outcome in FLT3-ITD-Positive AML Patients
    Shafik, Nevine F.
    Darwish, Amira D.
    Allam, Rasha Mahmoud
    Elsayed, Ghada M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10): : 676 - 685
  • [28] Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
    Iannotta, R.
    Celentano, M.
    Marotta, S.
    Pedata, C. M.
    Riccardi, C.
    Migliaccio, I.
    Viola, A.
    Muggianu, S. M.
    Falco, C.
    Bovenzi, D.
    Ferrara, F.
    Picardi, A.
    LEUKEMIA RESEARCH REPORTS, 2022, 18
  • [29] FLT3-ITD interacts with and phosphorylates IL-3β, and JAK1/2 dependent IL-3β activation bypasses FLT3-ITD in FLT3 kinase independent inhibitor resistance in vitro: Evidence for the significance of IL-3β for FLT3-ITD dependent oncogeneic signaling in AML
    Rummelt, C. A.
    Gorantla, S. P.
    Sigl, M.
    Saenger, J.
    Peschel, C.
    Duyster, J.
    Von Bubnoff, N.
    ONKOLOGIE, 2012, 35 : 89 - 89
  • [30] FLT3 AND FLT3-ITD GENE MUTATIONS AND PROGNOSIS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
    Chen, L. G.
    Pei, R. Z.
    Lu, Y.
    Zhang, P. S.
    Liu, X. H.
    Du, X. H.
    Chen, D.
    Cao, J. J.
    Li, S. Y.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2019, 33 (06): : 1855 - 1861
12345